CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
February 28 2023 - 5:58PM
CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level
1: CLVLY) today launched CYACÊLLE, a next generation of
polychromatic solar care. CYACÊLLE is designed to protect skin from
a wide spectrum of damaging solar radiation under extreme
conditions.
In the first launch phase, CYACÊLLE will be
available to individuals at high risk of photodamage and
photoageing from ultraviolet (UV) and high energy visible (HEV)
light exposure, and offered through CLINUVEL’s e-commerce channel
in Europe, www.CLINUVELDNA.com.
“It is clear that both UV and HEV light from
solar radiation damage skin,” CLINUVEL’s Chief Scientific Officer,
Dr Dennis Wright said. “We started off by working decades to
develop a world-first pharmaceutical product SCENESSE®
(afamelanotide) for patients affected by polychromatic – or
multiple wavelength – solar radiation.
“In a second phase, we have translated our
research and clinical data into the next generation of
polychromatic solar care products, λ3, to protect those at high
risk of photodamage and skin cancer. That resulted today in
CYACÊLLE.”
CYACÊLLE, is a leave-on cream offering shielding
from multiple wavelengths of light, and the first of four planned
product lines from CLINUVEL. The product was developed specifically
for individuals who spend excessive time near reflective surfaces,
those with a known history of solar skin damage and skin cancer,
and who are immune-suppressed, all of whom are at increased risk of
skin cancer.
Figure 1: Energy waves within the solar spectrum
which reach the Earth’s surface. Ultraviolet radiation has the
wavelength range of 190-400 nm; visible light has the wavelength
range of 400-700 nm (including HEV from 400-500nm); and infrared
radiation has the wavelength of 700-1,000 nm.
About CLINUVEL PHARMACEUTICALS
LIMITEDCLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; BÖRSE
FRANKFURT: UR9) is a global specialty pharmaceutical group focused
on developing and commercialising treatments for patients with
genetic, metabolic, systemic, and life-threatening, acute
disorders, as well as healthcare solutions for the general
population. As pioneers in photomedicine and the family of
melanocortin peptides, CLINUVEL’s research and development has led
to innovative treatments for patient populations with a clinical
need for systemic photoprotection, DNA repair, repigmentation and
acute or life-threatening conditions who lack alternatives.
CLINUVEL’s lead therapy, SCENESSE®
(afamelanotide 16mg), is approved for commercial distribution in
Europe, the USA, Israel and Australia as the world’s first systemic
photoprotective drug for the prevention of phototoxicity
(anaphylactoid reactions and burns) in adult patients with
erythropoietic protoporphyria (EPP). Headquartered in Melbourne,
Australia, CLINUVEL has operations in Europe, Singapore and the
USA. For more information, please go to
https://www.clinuvel.com.
CYACÊLLE®, SCENESSE®, PRÉNUMBRA®, and
NEURACTHEL® are registered trademarks of CLINUVEL.
Authorised for ASX release by the Board of
Directors of CLINUVEL PHARMACEUTICALS LTD
Media EnquiriesMonsoon
CommunicationsMr Rudi Michelson, 61 411 402 737,
rudim@monsoon.com.au
Head of Investor Relations Mr
Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD
Investor Enquiries
https://www.clinuvel.com/investors/contact-us
Forward-Looking Statements This
release contains forward-looking statements, which reflect the
current beliefs and expectations of CLINUVEL’s management. Please
see the full disclaimer on CLINUVEL’s website.
www.clinuvel.com
Level 11, 535 Bourke Street, Melbourne,
Victoria, Australia, 3000, T +61 3 9660 4900, F +61 3 9660
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ea934e49-a6c9-4cf7-80bd-d852c4a783ce
https://www.globenewswire.com/NewsRoom/AttachmentNg/e3e068e4-ddd4-4229-8959-10abf48468d2
https://www.globenewswire.com/NewsRoom/AttachmentNg/ff160192-c404-46c3-a7ad-6016ae172df9
Clinuvel Pharmaceuticals (TG:UR9)
Historical Stock Chart
From Nov 2024 to Dec 2024
Clinuvel Pharmaceuticals (TG:UR9)
Historical Stock Chart
From Dec 2023 to Dec 2024